USSTOCK.TODAY
Regular Market
Log in Sign up

Vertex Pharmaceuticals sees 12% Q3 revenue growth, investing profits into new ventures

The Motley Fool +3 · ·by G4L

DUOL
DUOL Duolingo Inc
$154.25 -3.85%
View chart & analysis →
  1. 1Vertex Pharmaceuticals recorded Q3 revenue of $3.44 billion.
  2. 2Vertex Pharmaceuticals saw an 8% decline in Trikafta revenue.
  3. 3Vertex Pharmaceuticals is deploying cystic fibrosis profits into new launches and the Crinetics deal.

So what's the key point?

Vertex Pharmaceuticals recorded $3.44 billion in Q3 revenue. While revenue from existing drugs decreased, the company is using those profits to invest in new businesses.

Source The Motley Fool +3 · View original ↗

Related 3-line summaries

Duolingo shares surge 26% on Wednesday following user spike The Motley Fool +1 · 5d agoDuolingo shares surge 27.3% following Q3 earnings release Schaeffer's Research +1 · 5d agoDuolingo to Report Q3 Earnings: Focus on User Growth and Monetization Earnings Whispers · Oct 27
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news